Status:

COMPLETED

Metabolic Effects of Switching Kaletra to Boosted Reyataz

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

HIV Infections

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.

Detailed Description

The primary objective of this study is to determine tissue specific glucose trafficking in patients before and after switching from a regimen containing Lopinavir/ritonavir (LPV/r) to one containing a...

Eligibility Criteria

Inclusion

  • Previously diagnosed HIV infection
  • Age between 18-65 years
  • Stable antiviral regimen containing at least 2 nucleoside reverse transcriptase inhibitors (NRTI's) and LPV/r for ³ 6 mos
  • CD4 count \> 400 cell/mm3
  • Metabolic complication as indicated by one or more of hyperinsulinemia (fasting insulin \>= 15 mIU/ml), hypercholesteremia (fasting total cholesterol \>= 200 mg/dL), hypertriglyceridemia (fasting triglycerides \>= 150 mg/dL), or treatment with a lipid lowering medication.

Exclusion

  • Hemoglobin \< 11.0 g/dL
  • History of Diabetes Mellitus
  • Currently on medication for Diabetes
  • Therapy with glucocorticoid, growth hormone or other anabolic agents currently or within the past 3 months
  • Current substance abuse, including alcohol, cocaine and/or heroin
  • Any contraindication to ATV/r or known allergy to ATV
  • Concurrent therapy with: Bepridil; cisapride; ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine); indinavir; irinotecan; lovastatin; midazolam; pimozide; proton pump inhibitors (esomeprazole, lansoprazole, omeprazole); rifampin; simvastatin; St John's wort; or triazolam
  • New or serious opportunistic infection in the past 3 months
  • Pregnancy

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00413153

Start Date

May 1 2006

End Date

December 1 2008

Last Update

March 9 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114